Treatment News : Most HIV-Positive People Vaccinated for Hep A Have a Durable Response

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » June 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


June 15, 2011

Most HIV-Positive People Vaccinated for Hep A Have a Durable Response

A substantial number of people with HIV who are vaccinated against hepatitis A virus (HAV) maintain their initial antibody response to the virus for up to 10 years, according to a study published in the June 15 issue of The Journal of Infectious Diseases. The authors comment however, that because these response rates are still lower than in HIV-negative people, we should, perhaps be giving HIV-positive people an additional vaccine booster shot.

Hepatitis A—while not deadly like chronic hepatitis B virus (HBV) or hepatitis C virus (HCV)—does cause a serious and very unpleasant illness in many people. Symptoms of HAV infection include fevers, stomach upset and extreme fatigue, and they can sometimes last for more than two months.

Fortunately, there is a vaccine that protects people from contracting HAV. It is both effective and long lasting in HIV-negative people, but little is known about the vaccine’s efficacy and durability in people with HIV.

To address this unanswered question, Nancy Crum-Cianflone, MD, from the Naval Medical Center in San Diego, and her colleagues, looked backward at the medical records of 130 HIV-positive people enrolled in the U.S. Military HIV Natural History Study. Results from the HAV antibody tests were available for all participants at the one- and three-year mark following vaccination. Antibody results from six to 10 years after vaccination were available in a smaller group. Vaccines were given between 1996 and 2003, and people were followed until 2007.

The participants’ average age was 35, and just less than half had a viral load under 1,000 copies. Nine percent of the participants had chronic HBV infection, and 2 percent had chronic HCV infection at the time of vaccination.

Crum-Cianflone and her fellow scientists found that antibody responses were good in people with HIV, though not quite as good as in HIV-negative people. Eighty-nine percent of the HIV-positive study participants initially had strong antibody responses to the vaccine, compared with 100 percent of HIV-negative people from historical studies.

What’s more, antibody responses in those living with HIV were quite durable. In those who initially had good antibody responses, 90 percent maintained them for at least three years and 85 percent maintained them for between six and 10 years.

The research team found that a person’s CD4 count had an initial impact on vaccine durability. Those with a CD4 count over 350 were more likely to have an initial vaccine response than those with CD4s under 350. People with higher CD4s also had slightly higher antibody levels three years after vaccination, but after six years there was no difference.

Viral load, on the other hand, did have a lasting impact on a person’s initial response to the vaccine as well as his or her likelihood of maintaining that response over the long-term.

Another key finding was that the number of antibodies present in a tiny amount of blood over time was substantially lower in people with HIV than in their HIV-negative counterparts, and the number of antibodies present at between six and 10 years after vaccination began to approach ineffective levels.

The authors suggest that an additional booster shot of the vaccine might help improve initial response rates as well as help maintain antibody levels over time. They also conclude, “Maintaining [lower] HIV RNA levels among HIV-infected persons may be an important strategy for sustaining durable antibody levels for vaccine preventable infections such as hepatitis A virus.”

Search: Hepatitis A virus, HAV, hep A, hepatitis B virus, HBV, hepatitis C virus, HCV, vaccine, Nancy Crum-Cianflone, Naval Medical Center, San Diego

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.